Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 26, 2026Viral Hepatitis JournalOpen Access

Hepatitis B Reactivation and Antiviral Prophylaxis in Patients on Immunosuppressive Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYakup GezerATArzu Tarakçı

Discussion

Loading...

Member takes

Overview

Retrospective study reveals zero hepatitis B reactivation with antiviral prophylaxis in immunosuppressed patients, highlighting the necessity of risk-stratified preventative therapy.

Key Points

  • To assess hepatitis B virus reactivation rates among immunosuppressed patients managed with or without antiviral prophylaxis.
  • Retrospective, single-center evaluation at a tertiary-care hospital including 153 patients receiving immunosuppressive therapy who tested positive for hepatitis B surface antigen (HBsAg) or core antibody.
  • Antiviral prophylaxis regimens evaluated included entecavir (75.2%), tenofovir disoproxil fumarate (19.2%), and tenofovir alafenamide (5.6%).
  • Hepatitis B reactivation occurred in 0% of patients receiving antiviral prophylaxis versus 2 unprophylaxed patients (p=0.033), one treated with rituximab and one with corticosteroids.
  • Among patients without prophylaxis, reactivation rates by risk tier were 50% in the high-risk group, 25% in the moderate-risk group, and 0% in the low-risk group.

Cite This Study

Gezer et al. (2026) studied this question.

synapsesocial.com/papers/6a9417fa219df916ad43f442https://doi.org/10.4274/vhd.galenos.2026.2025-10-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hepatitis B Prophylaxis Outcomes in Patients Receiving Immunosuppressive Therapy: A Retrospective Cohort Study2026
  2. 2Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation2022 · 1 citations
  3. 3Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents2026 · 1 citations
  4. 4Risk of Hepatitis B Virus Reactivation in COVID-19 Patients Receiving Immunosuppressive Treatment – Prospective Study2024 · 2 citations
  5. 5Hepatitis B reactivation with TNF-α inhibitors: assessing antiviral prophylaxis efficacy — protocol for systematic review and meta-analysis2025 · 1 citations